Sandoz Receives FDA’s Clearance for reSET-O, a Medical Mobile App for Opioid Use Disorder (OUD)

 Sandoz Receives FDA’s Clearance for reSET-O, a Medical Mobile App for Opioid Use Disorder (OUD)

Sandoz Receives FDA’s Clearance for reSET-O, a Medical Mobile App for Opioid Use Disorder (OUD)

Shots:

  • The approval is based on trial results assessing reSET-O in 170 patients receiving either treatment-as-usual (TAU) + standard clinician interactions + buprenorphine or reSET-O + standard clinician interactions + buprenorphine for 12 wks.
  • The study demonstrated improved and increase rates of retention time with efficacy results in patients with OUD
  • reSET-O is a FDA approved Prescription Digital Therapeutic mobile medical application for 12 weeks, delivering a cognitive behavioral therapy for OUD patients aged ≥18 yrs. In Nov 2018, reSET received FDA approval for Substance Use Disorder (SUD)

Click here to read full press release/ article | Ref: Novartis| Image: Medical Product Outsourcing

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post